AstraZeneca, Daiichi announce ENHERTU showed improvement in IDFS

Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival, IDFS, compared to trastuzumab emtansine as a post-neoadjuvant treatment in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. Results were presented alongside the results of DESTINY-Breast11 in Presidential Symposium I at the 2025 European Society for Medical Oncology Congress. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo (DSNKY) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). In the primary endpoint analysis, ENHERTU significantly reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 as a post-neoadjuvant treatment. ENHERTU demonstrated a three-year IDFS rate of 92.4% compared to 83.7% with T-DM1. IDFS findings were consistent across all prespecified subgroups.